Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Mycoses ; 64(6): 616-623, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33555073

RESUMEN

BACKGROUND: The genus Blastobotrys consists of at least 20 species. Disease in humans has been reported with B adeninivorans, B raffinosifermentans, B proliferans and B serpentis, mostly in immunocompromised patients and those with cystic fibrosis. OBJECTIVE: We report a lung infection secondary to B raffinosifermentans in a cystic fibrosis patient successfully treated with isavuconazole and review the literature of invasive infections caused this genus. We also evaluated clinical isolates in our laboratory for species identification and antifungal susceptibility. METHODS: Phylogenetic analysis was performed on a collection of 22 Blastobotrys isolates in our reference laboratory, and antifungal susceptibility patterns were determined for nine clinically available antifungals against 19 of these isolates. RESULTS: By phylogenetic analysis, 21 of the 22 isolates in our collection were identified as B raffinosifermentans and only 1 as B adeninivorans. Most were cultured from the respiratory tract, although others were recovered from other sources, including CSF and blood. Isavuconazole, caspofungin and micafungin demonstrated the most potent in vitro activity, followed by amphotericin B. In contrast, fluconazole demonstrated poor activity. The patient in this case responded to isavuconazole treatment for breakthrough infection due to B raffinosifermentans that was cultured from pleural fluid while on posaconazole prophylaxis post-bilateral lung transplantation for cystic fibrosis. CONCLUSIONS: Blastobotrys species are rare causes of infections in humans and primarily occur in immunocompromised hosts. In our collection, the majority of isolates were identified as B raffinosifermentans. To our knowledge, this is the first report of successful treatment of such an infection with isavuconazole.


Asunto(s)
Fibrosis Quística/complicaciones , Nitrilos/uso terapéutico , Neumonía , Piridinas/uso terapéutico , Saccharomycetales , Triazoles/uso terapéutico , Adulto , Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Fibrosis Quística/microbiología , Femenino , Fluconazol/uso terapéutico , Genes Fúngicos , Humanos , Terapia de Inmunosupresión/efectos adversos , Pruebas de Sensibilidad Microbiana , Micosis/complicaciones , Micosis/tratamiento farmacológico , Filogenia , Neumonía/tratamiento farmacológico , Neumonía/microbiología , Neumonía/patología , Saccharomycetales/genética , Saccharomycetales/aislamiento & purificación , Saccharomycetales/patogenicidad
2.
J Transl Med ; 18(1): 205, 2020 05 19.
Artículo en Inglés | MEDLINE | ID: mdl-32430070

RESUMEN

The COVID-19 pandemic has become the leading societal concern. The pandemic has shown that the public health concern is not only a medical problem, but also affects society as a whole; so, it has also become the leading scientific concern. We discuss in this treatise the importance of bringing the world's scientists together to find effective solutions for controlling the pandemic. By applying novel research frameworks, interdisciplinary collaboration promises to manage the pandemic's consequences and prevent recurrences of similar pandemics.


Asunto(s)
Investigación Biomédica/organización & administración , Infecciones por Coronavirus/epidemiología , Prestación Integrada de Atención de Salud/organización & administración , Urgencias Médicas , Necesidades y Demandas de Servicios de Salud , Pandemias , Neumonía Viral/epidemiología , Betacoronavirus/patogenicidad , Investigación Biomédica/métodos , COVID-19 , Infecciones por Coronavirus/terapia , Infecciones por Coronavirus/virología , Prestación Integrada de Atención de Salud/métodos , Historia del Siglo XXI , Humanos , Comunicación Interdisciplinaria , Estudios Interdisciplinarios , Neumonía Viral/terapia , Neumonía Viral/virología , Salud Pública/historia , Salud Pública/normas , SARS-CoV-2
3.
Anticancer Agents Med Chem ; 19(17): 2140-2153, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31736448

RESUMEN

BACKGROUND: Green synthesis of silver nanoparticles (AgNPs) is limited to produce AgNPs with only relatively low concentrations, and is unsuitable for large-scale productions. The use of Myrtus communis (MC) leaf methanolic extract (rich in hydrolyzable tannins) has been recommended to resolve the issues related to the aggregation of nanoparticles at high concentrations of silver ions with added facet of antioxidant properties. METHODS: The produced highly concentrated MC-AgNPs were characterized by using imaging and spectroscopic methods. Subsequently, antioxidant, anticancer and antifungal activities of the nanoparticles were evaluated. RESULTS: The thermogravimetric analysis and energy dispersive spectroscopy quantitative results suggested that the nanoparticles are biphasic in nature (bio-molecule + Ag0) and layered in structure, suggesting the formation of nanoparticles through a different mechanism than those described in the literature. MC-AgNPs showed greater scavenging activity of nitric oxide and iron (II) chelating ability than the extract. It also showed good reducing power compared to the standard antioxidant. Remarkable anticancer activity of MC-AgNPs (IC50 = 5.99µg/mL) was found against HCT-116 (human colon carcinoma) cell lines after 24h exposure with a therapeutic index value 2-fold higher than the therapeutic index of standard doxorubicin. Furthermore, distinct antifungal activity (MIC = 4µg/mL) was found against Candida krusei. CONCLUSION: The current method outperforms the existing methods because it produces a large amount of multifunctional nanoscale hybrid materials more efficiently using natural sources; thus, it may be used for diverse biomedical applications.


Asunto(s)
Antifúngicos/farmacología , Antioxidantes/farmacología , Candida/efectos de los fármacos , Nanopartículas/química , Plata/farmacología , Antifúngicos/química , Antioxidantes/química , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Humanos , Iones/química , Iones/farmacología , Pruebas de Sensibilidad Microbiana , Oxidación-Reducción , Plata/química
4.
Bioorg Med Chem ; 23(7): 1481-91, 2015 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-25740636

RESUMEN

In order to find new azole antifungals, we have recently designed a series of triazole alcohols in which one of the 1,2,4-triazol-1-yl group in fluconazole structure has been replaced with 4-amino-5-aryl-3-mercapto-1,2,4-triazole motif. In this paper, we focused on the structural refinement of the primary lead, by removing the amino group from the structure to achieve 5-aryl-3-mercapto-1,2,4-triazole derivatives 10a-i and 11a-i. The in vitro antifungal susceptibility testing of title compounds demonstrated that most compounds had potent inhibitory activity against Candida species. Among them, 5-(2,4-dichlorophenyl)triazole analogs 10h and 11h with MIC values of <0.01 to 0.5µg/mL were 4-256 times more potent than fluconazole against Candida species.


Asunto(s)
Antifúngicos/síntesis química , Fluconazol/análogos & derivados , Fluconazol/síntesis química , Triazoles/síntesis química , Antifúngicos/farmacología , Supervivencia Celular/efectos de los fármacos , Evaluación Preclínica de Medicamentos/métodos , Fluconazol/farmacología , Células Hep G2 , Humanos , Pruebas de Sensibilidad Microbiana , Triazoles/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA